Literature DB >> 12351957

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

Eva Poveda1, Berta Rodés, Carlos Toro, Luz Martín-Carbonero, Juan Gonzalez-Lahoz, Vincent Soriano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12351957     DOI： 10.1097/00002030-200209270-00014

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  22 in total

1.  Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Authors:  Min Zhuang; Wei Wang; Christopher J De Feo; Russell Vassell; Carol D Weiss
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

Review 2.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.

Authors:  Daisuke Nameki; Eiichi Kodama; Mieko Ikeuchi; Naoto Mabuchi; Akira Otaka; Hirokazu Tamamura; Mutsuhito Ohno; Nobutaka Fujii; Masao Matsuoka
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.

Authors:  Min Zhuang; Russell Vassell; Chen Yuan; Paul W Keller; Hong Ling; Wei Wang; Carol D Weiss
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

5.  Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Authors:  L Xu; A Pozniak; A Wildfire; S A Stanfield-Oakley; S M Mosier; D Ratcliffe; J Workman; A Joall; R Myers; E Smit; P A Cane; M L Greenberg; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Authors:  Emmanuel Desmezieres; Nidhi Gupta; Russell Vassell; Yong He; Keith Peden; Lev Sirota; Zhongning Yang; Paul Wingfield; Carol D Weiss
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.

Authors:  Stefano Menzo; Antonella Castagna; Alessia Monachetti; Hamid Hasson; Anna Danise; Elisabetta Carini; Patrizia Bagnarelli; Adriano Lazzarin; Massimo Clementi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.

Authors:  Marintha L Heil; Julie M Decker; Jeffrey N Sfakianos; George M Shaw; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant.

Authors:  Chris Baldwin; Ben Berkhout
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Authors:  Dirk Eggink; Christopher E Baldwin; Yiqun Deng; Johannes P M Langedijk; Min Lu; Rogier W Sanders; Ben Berkhout
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.